Has Kopran declared dividend?

Kopran Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 2, 2024. Despite recent price declines, the company has shown positive long-term returns, with a current dividend yield of 1.55%.

Kopran Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 02 Sep 24<BR><BR>Dividend Yield: 1.55%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -11.22%, with a dividend return of 0%, resulting in a total return of -11.22%.<BR><BR>Over the past year, the price return was -18.86%, the dividend return was 1.26%, leading to a total return of -17.6%.<BR><BR>In the 2-year period, the price return was 8.97%, the dividend return was 3.32%, culminating in a total return of 12.29%.<BR><BR>For the 3-year period, the price return was -13.38%, with a dividend return of 4.89%, resulting in a total return of -8.49%.<BR><BR>In the last 4 years, the price return was -0.42%, the dividend return was 4.99%, leading to a total return of 4.57%.<BR><BR>Over the 5-year period, the price return was 559.45%, with a dividend return of 35.14%, resulting in a total return of 594.59%.<BR><BR>Overall, while Kopran has declared a dividend and has shown positive returns over the long term, recent performance indicates significant declines in price returns, particularly in the shorter time frames. The dividend yield suggests that the company is providing some return to shareholders despite the fluctuations in price.

Who are the peers of the Kopran?

Kopran's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Kopran has average management risk and a good capital structure, its 1-year return is -12.11%, compared to Divi's Lab's highest return of 51.96%.

Peers: The peers of Kopran are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Parenter., Shree Ganesh Rem, Kilitch Drugs, NGL Fine Chem, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Kopran, Bharat Parenter., Shree Ganesh Rem, Sakar Healthcare, and the rest. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Kilitch Drugs, while below average growth is noted at Divi's Lab., Torrent Pharma, Kopran, Bharat Parenter., NGL Fine Chem, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Shree Ganesh Rem, and NGL Fine Chem, while average capital structure is found at Bharat Parenter. and Sakar Healthcare, and good capital structure is noted at Kopran and Kilitch Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while NGL Fine Chem has the lowest at -52.32%. Kopran's own 1-year return is -12.11%, which is significantly lower than the highest peer return and higher than the lowest. Additionally, the peers with negative six-month returns include Bharat Parenter., NGL Fine Chem, and Shree Ganesh Rem.

Is Kopran overvalued or undervalued?

As of February 12, 2025, Kopran is considered fairly valued with a PE Ratio of 24.22 and has underperformed the Sensex with a return of -18.93%, indicating limited growth expectations compared to its peers.

As of 12 February 2025, Kopran's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 24.22, an EV to EBITDA of 15.13, and a Price to Book Value of 1.80, which suggest that while Kopran is priced reasonably compared to its earnings and book value, it may not present a significant discount to peers.<BR><BR>In comparison to its peers, Kopran's PE Ratio is lower than that of Sun Pharma (35.25) and Divi's Lab (79.33), both categorized as expensive, while it is slightly higher than Cipla (22.99) and Dr. Reddy's Labs (19.49), which are also attractive. Notably, Kopran's PEG Ratio is 0.00, indicating no growth expectations priced into the stock, which could be a concern for potential investors. Over the past year, Kopran has underperformed the Sensex, with a return of -18.93% compared to the Sensex's 7.61%, reinforcing the notion that the stock may not be positioned for significant growth in the near term.

Who are in the management team of Kopran?

As of March 2023, the management team of Kopran includes Surendra Somani (Executive Vice Chairman), Sunil Sodhani (Company Secretary), and several independent directors, along with non-executive members like Susheel Somani (Chairman) and Adarsh and Varun Somani.

As of March 2023, the management team of Kopran includes the following individuals:<BR><BR>1. Surendra Somani - Executive Vice Chairman<BR>2. Sunil Sodhani - Company Secretary & Compliance Officer<BR>3. Siddhan Subramanian - Independent Director<BR>4. Sunita Banerji - Independent Director<BR>5. Mamta Biyani - Independent Director<BR>6. Narayan Atal - Independent Director<BR>7. Susheel Somani - Chairman (Non-Executive)<BR>8. Adarsh Somani - Non-Executive Director<BR>9. Varun Somani - Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Kopran do?

Kopran Ltd is a micro-cap pharmaceutical and biotechnology company that manufactures finished dosage forms and bulk drugs. As of March 2025, it reported net sales of ₹1,724 Cr and a net profit of ₹97 Cr.

Overview: <BR>Kopran Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market, specializing in the manufacture of pharmaceutical finished dosage forms and bulk drugs.<BR><BR>History: <BR>Kopran Ltd was incorporated on April 26, 1958. The company went public in November 1992 to finance its backward integration project for producing drug intermediates and to expand its antibiotic facility. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,724 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 97 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 866 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.67% <BR>Debt Equity: 0.24 <BR>Return on Equity: 7.44% <BR>Price to Book: 1.67 <BR><BR>Contact Details: <BR>Address: Parijat House 1076, Dr E Moses Road Worli Mumbai Maharashtra : 400018 <BR>Tel: 91-22-43661111 <BR>Email: investors@kopran.com <BR>Website: http://www.kopran.com

Who are the top shareholders of the Kopran?

The top shareholders of Kopran include Oricon Enterprises Limited with 12.88%, individual investors with 42.83%, and Laxminarayan Vyapaar P Ltd at 1.56%. Additionally, there are 29 foreign institutional investors holding 0.76%, and no pledged promoter holdings are reported.

The top shareholders of Kopran include Oricon Enterprises Limited, which holds the highest promoter stake at 12.88%. Additionally, individual investors collectively own 42.83% of the company. Among public shareholders, Laxminarayan Vyapaar P Ltd is notable with a holding of 1.56%. The company also has 29 foreign institutional investors (FIIs) with a combined holding of 0.76%, and there are five mutual fund schemes that hold 0.0%. There are no pledged promoter holdings reported.

How big is Kopran?

As of 24th July, Kopran Ltd has a market capitalization of 853.00 Cr, with recent net sales of 629.60 Cr and a net profit of 38.56 Cr. Shareholder's funds are 491.25 Cr, and total assets amount to 743.25 Cr as of March 2024.

As of 24th July, Kopran Ltd has a market capitalization of 853.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Kopran reported Net Sales of 629.60 Cr and a Net Profit of 38.56 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 491.25 Cr and Total Assets of 743.25 Cr.

When is the next results date for Kopran?

The next results date for Kopran is 12 November 2025.

The next results date for Kopran is scheduled for 12 November 2025.

How has been the historical performance of Kopran?

Kopran's historical performance shows steady sales growth from INR 359.50 crore in March 2020 to INR 629.60 crore in March 2025, but profitability has declined, with profit after tax dropping from INR 61.61 crore in March 2021 to INR 38.55 crore in March 2025 due to rising costs. Total assets increased significantly, while cash flow from operating activities remained positive.

Answer:<BR>The historical performance of Kopran shows a mixed trend in financial metrics over the years, with notable fluctuations in sales, profits, and expenses.<BR><BR>Breakdown:<BR>Kopran's net sales have shown a steady increase from INR 359.50 crore in March 2020 to INR 629.60 crore in March 2025, reflecting a strong growth trajectory. However, the total operating income also increased correspondingly, reaching INR 629.60 crore in March 2025. The raw material costs have risen significantly, from INR 196.19 crore in March 2019 to INR 401.00 crore in March 2025, indicating rising input costs. Operating profit, excluding other income, peaked at INR 99.76 crore in March 2021 but has since declined to INR 72.89 crore in March 2025. Profit before tax followed a similar pattern, reaching a high of INR 83.34 crore in March 2021 before dropping to INR 51.95 crore in March 2025. Consequently, profit after tax also decreased from INR 61.61 crore in March 2021 to INR 38.55 crore in March 2025. The company's total assets have grown from INR 370.21 crore in March 2020 to INR 844.01 crore in March 2025, while total liabilities increased from INR 370.21 crore to INR 147.79 crore over the same period. Cash flow from operating activities remained positive, with INR 41.00 crore in March 2025, although cash flow from investing activities was negative at INR -56.00 crore. Overall, Kopran's financial performance reflects growth in sales and assets but challenges in maintaining profitability amidst rising costs.

Is Kopran technically bullish or bearish?

As of November 12, 2025, Kopran's technical trend has shifted to bearish, supported by negative indicators from MACD, Bollinger Bands, and moving averages, despite a mildly bullish signal from KST on the weekly chart.

As of 12 November 2025, the technical trend for Kopran has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish outlook. Daily moving averages confirm the bearish trend. Although the KST shows a mildly bullish signal on the weekly, the overall monthly trend remains bearish. Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. The stock has experienced significant declines over various time frames, further supporting the bearish sentiment.

Are Kopran latest results good or bad?

Kopran's latest Q2 FY26 results are concerning, showing a net loss of ₹9.92 crores and a 22.20% drop in revenue year-on-year. This marks the company's first quarterly loss and indicates significant operational challenges and declining financial health.

Kopran's latest results for Q2 FY26 are concerning and indicate a significant decline in performance. The company reported a net loss of ₹9.92 crores, which is a staggering 234.42% decrease year-on-year. This marks a troubling shift, as it is the first quarterly loss in recent history for the company.<BR><BR>Revenue for the quarter also fell sharply, down 22.20% year-on-year to ₹117.91 crores, reflecting ongoing operational challenges. The operating margin turned negative at -4.48%, the lowest it has been in eight quarters, indicating that the company is struggling to manage its costs effectively in relation to its sales.<BR><BR>Additionally, the return on equity (ROE) for the first half of FY26 stands at a weak 7.44%, which is below industry standards and suggests that the company is not generating adequate returns on its investments. Overall, these results highlight a severe deterioration in Kopran's financial health and operational efficiency, raising concerns about its ability to navigate the current market environment.

Should I buy, sell or hold Kopran?

Why is Kopran falling/rising?

As of 15-Dec, Kopran Ltd's stock price is rising to 131.70, driven by a positive short-term trend and increased investor participation. Despite recent gains, the stock remains below its longer-term moving averages.

As of 15-Dec, Kopran Ltd's stock price is rising, currently at 131.70, with a change of 0.8 (0.61%) upward. This increase can be attributed to a few key factors. Firstly, the stock has been gaining for the last three days, with a total return of 0.88% during this period, indicating a positive short-term trend. Additionally, the stock has outperformed its sector by 0.46% today, suggesting that it is performing better relative to its peers.<BR><BR>Moreover, there has been a rise in investor participation, as evidenced by a delivery volume of 75.52k on December 12, which is up by 1.68% compared to the 5-day average delivery volume. This increase in trading activity may reflect growing interest among investors, contributing to the upward movement in the stock price.<BR><BR>However, it is important to note that despite the recent gains, Kopran's stock is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it has not yet recovered to its longer-term performance levels. Overall, the combination of recent gains, improved investor participation, and sector outperformance are the primary reasons for the stock's rise on this date.

Which are the latest news on Kopran?